The DOI matches its Crossref record; 217 of the 218 references it cites were found in a registry or an index.
Toxicokinetics and Toxicodynamics of Ayahuasca Alkaloids N,N-Dimethyltryptamine (DMT), Harmine, Harmaline and Tetrahydroharmine: Clinical and Forensic Impact
Open accessAbstract
Ayahuasca is a hallucinogenic botanical beverage originally used by indigenous Amazonian tribes in religious ceremonies and therapeutic practices. While ethnobotanical surveys still indicate its spiritual and medicinal uses, consumption of ayahuasca has been progressively related with a recreational purpose, particularly in Western societies. The ayahuasca aqueous concoction is typically prepared from the leaves of the N,N-dimethyltryptamine (DMT)-containing Psychotria viridis, and the stem and bark of Banisteriopsis caapi, the plant source of harmala alkaloids. Herein, the toxicokinetics and toxicodynamics of the psychoactive DMT and harmala alkaloids harmine, harmaline and tetrahydroharmine, are comprehensively covered, particularly emphasizing the psychological, physiological, and toxic effects deriving from their concomitant intake. Potential therapeutic utility, particularly in mental and psychiatric disorders, and forensic aspects of DMT and ayahuasca are also reviewed and discussed. Following administration of ayahuasca, DMT is rapidly absorbed and distributed. Harmala alkaloids act as potent inhibitors of monoamine oxidase A (MAO-A), preventing extensive first-pass degradation of DMT into 3-indole-acetic acid (3-IAA), and enabling sufficient amounts of DMT to reach the brain. DMT has affinity for a variety of serotonergic and non-serotonergic receptors, though its psychotropic effects are mainly related with the activation of serotonin receptors type 2A (5-HT2A). Mildly to rarely severe psychedelic adverse effects are reported for ayahuasca or its alkaloids individually, but abuse does not lead to dependence or tolerance. For a long time, the evidence has pointed to potential psychotherapeutic benefits in the treatment of depression, anxiety, and substance abuse disorders; and although misuse of ayahuasca has been diverting attention away from such clinical potential, research onto its therapeutic effects has now strongly resurged.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Harmine as a MAO-I was chosen, because it’s a major psychoactive molecule of the ayahuasca brew with a favorable side effect profile, e.g., lower toxicity compared to harmaline, and because it’s selective and reversible (55).”
From Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects (2024) · cites this paper as [55]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Predicting new molecular targets for known drugs
Keiser, M. J., Setola, V., Irwin, J. J., Laggner, C., Abbas, A. I., Hufeisen, S. J., Jensen, N. H., Kuijer, M. B., Matos, R. C., Tran, T. B., et al. (2009) · Nature · doi:10.1038/nature08506 · Cited by 1,667
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Human hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
Jones, M. W., Errington, M. L., French, P. J., Fine, A., Bliss, T., Garel, S., Charnay, P., Bozon, B., Laroche, S., & Davis, S. (2001) · Nature Neuroscience · doi:10.1038/85138 · Cited by 925
González-Maeso, J., Weisstaub, N. V., Zhou, M., Chan, P., Ivic, L., Ang, R., Lira, A., Bradley-Moore, M., Ge, Y., Zhou, Q., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.008 · Cited by 925
Pompeiano, M., Palacios, J. M., & Mengod, G. (1994) · Molecular Brain Research · doi:10.1016/0169-328x(94)90223-2 · Cited by 870
Palhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C., Novaes, M. M., Pessoa, J. A., Mota-Rolim, S. A., Osório, F. L., Sanches, R., dos Santos, R. G., et al. (2019) · Psychological Medicine · doi:10.1017/s0033291718001356 · Cited by 852
Serotonin and brain function: a tale of two receptors
Carhart-Harris, R., & Nutt, D. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117725915 · Cited by 739
Flagged first, then by citations
1 of the 218 references couldn’t be matched to a known paper.
Research works printed but not linked: 12
- Strassman, R.J. (2001). DMT: The Spirit Molecule: A Doctor’s Revolutionary Research into the Biology of Near-Death and Mystical Experiences, Park Street Press.
- Rall, T.W., Nies, A.S., and Taylor, P. (1990). Drug addiction and drug abuse. Goodman and Gilman’s the Pharmacological Basis of Therapeutics, McGraw-Hill.
- Hardman, J.G., Limbird, L.E., Molinoff, P.B., Ruddon, R.W., and Gilman, A.G. (2018). Drug Use Disorders and Addiction. Goodman and Gilman’s the Pharmacological Basis of Therapeutics, McGraw-Hill.
- Hofmann, A. (1976). LSD—My Problem Child, McGraw-Hill.
- Schultes, 1972, Ethnotoxocological significance of additives to New World hallucinogens, Plant Sci. Bull., 18, 34
- Moffat, A.C., Osselton, M.D., Widdop, B., and Watts, J. (2011). Clarke’s Analysis of Drugs and Poisons, Pharmaceutical Press. [4th ed.].
- National Center for Biotechnology Information (2020, July 29). PubChem Compound Summary for CID 6089, N,N-Dimethyltryptamine, Available online: https://pubchem.ncbi.nlm.nih.gov/compound/N_N-Dimethyltryptamine.
- National Center for Biotechnology Information (2020, July 29). PubChem Compound Summary for CID 3564, Harmaline, Available online: https://pubchem.ncbi.nlm.nih.gov/compound/Harmaline.
- National Center for Biotechnology Information (2020, July 29). PubChem Compound Summary for CID 159809, Tetrahydroharmine, Available online: https://pubchem.ncbi.nlm.nih.gov/compound/Tetrahydroharmine.
- Naranjo, 1959, Estudio comparativo de la harmina, la dietilamida del ácido lisérgico (LSD-25) y la mescalina, Rev. Confed. Médica Panam., 6, 1
- Warren, 2004, Fatal nicotine intoxication resulting from the ingestion of “ayahuasca”, J. Anal. Toxicol., 28, 287
- Metzner, R. (1999). The psychology of ayahuasca. Ayahuasca: Hallucinogens, Consciousness, and the Spirit of Nature, Thunder’s Mouth Press.
Cited by
Sorted by citations
D’Souza, D. C., Syed, S. A., Flynn, L. T., Safi-Aghdam, H., Cozzi, N. V., & Ranganathan, M. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01344-y · Cited by 162
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment
Zaretsky, T. G., Jagodnik, K. M., Barsic, R., Antonio, J. H., Bonanno, P. A., MacLeod, C., Pierce, C., Carney, H., Morrison, M. T., Saylor, C. F., et al. (2024) · Current Neuropharmacology · doi:10.2174/1570159x22666231027111147 · Cited by 92
Drug–drug interactions involving classic psychedelics: A systematic review
Halman, A., Kong, G., Sarris, J. J., & Perkins, D. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231211219 · Cited by 78
Biosynthesis and synthetic biology of psychoactive natural products
Jamieson, C. S., Misa, J., Tang, Y., & Billingsley, J. M. (2021) · Chemical Society Reviews · doi:10.1039/d1cs00065a · Cited by 74
Rosenblat, J. D., Husain, M. I., Lee, Y. L., McIntyre, R. S., Mansur, R. B., Castle, D. J., Offman, H., Parikh, S. V., Frey, B. N., Schaffer, A., et al. (2022) · The Canadian Journal of Psychiatry · doi:10.1177/07067437221111371 · Cited by 68
Segers, A., & de Vos, W. M. (2023) · Microbiome Research Reports · doi:10.20517/mrr.2023.05 · Cited by 69
Exploring DMT: Endogenous role and therapeutic potential
Schimmelpfennig, J., & Jankowiak-Siuda, K. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110314 · Cited by 55
The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology
Mastinu, A., Anyanwu, M., Carone, M., Abate, G., Bonini, S. A., Peron, G., Tirelli, E., Pucci, M., Ribaudo, G., Oselladore, E., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021329 · Cited by 52
Ayahuasca's therapeutic potential: What we know – and what not
Maia, L. O., Daldegan‐Bueno, D., Wießner, I., de Araújo, D. B., & Tófoli, L. F. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.10.008 · Cited by 54
Brito-da-Costa, A. M., da Silva, D. D., Gomes, N. G. M., Dinis‐Oliveira, R. J., & Madureira-Carvalho, Á. (2021) · Pharmaceuticals · doi:10.3390/ph14020116 · Cited by 44
Self-citationN,N‐dimethyltryptamine and Amazonian ayahuasca plant medicine
James, E., Keppler, J., Robertshaw, T. L., & Sessa, B. (2022) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2835 · Cited by 50
Berlowitz, I., Egger, K., & Cumming, P. D. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.886408 · Cited by 40
Egger, K., Aicher, H., Cumming, P. D., & Scheidegger, M. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05353-6 · Cited by 37
Więckiewicz, G., Stokłosa, I., Piegza, M. J., Gorczyca, P. W., & Pudło, R. (2021) · Pharmaceuticals · doi:10.3390/ph14080793 · Cited by 34
Aicher, H. D., Mueller, M. J., Dornbierer, D. A., Suay, D., Elsner, C., Wicki, I., Meling, D., Caflisch, L., Hempe, A., Steinhart, C., et al. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1302559 · Cited by 33
The evolution of N, N-Dimethyltryptamine: from metabolic pathways to brain connectivity
Gupta, S., Bhatnagar, R. K., Gupta, D., Maharaj Kumari, K., & Chopra, A. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06777-z · Cited by 32
Larit, F., & León, F. (2023) · Plants · doi:10.3390/plants12223860 · Cited by 30
Thangavelu, L. P., Altamimi, A. S., Ghaboura, N., Babu, M. A., Roopashree, R., Sharma, P., Pal, P., Choudhary, C., Prasad, G. V. S., Sinha, A., et al. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155652 · Cited by 30
Werle, I., Nascimento, L. M. M., dos Santos, A. L. A., Soares, L. A., SANTOS, R. G. D., Hallak, J. E. C., & Bertoglio, L. J. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16315 · Cited by 28
Politi, M., Tresca, G., Menghini, L., & Ferrante, C. (2021) · Planta Medica · doi:10.1055/a-1675-3840 · Cited by 25
Ayahuasca blocks ethanol preference in an animal model of dependence and shows no acute toxicity
Gianfratti, B., Tabach, R., Sakalem, M. E., Stessuk, T., Maia, L. O., & Carlini, E. A. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114865 · Cited by 25
Eckernäs, E., Timmermann, C., Carhart-Harris, R. L., Röshammar, D., & Ashton, M. (2022) · Clinical and Translational Science · doi:10.1111/cts.13410 · Cited by 25
Formagio, A. S. N., Vilegas, W., Volobuff, C. R. F., Kassuya, C. A. L., Cardoso, C. A. L., Pereira, Z. V., Mussury, R. M., Yamazaki, D. A. D. S., Gauze, G. F., Manfron, J., et al. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115220 · Cited by 23
Glavonic, E., Mitić, M., & Adžić, M. (2022) · Journal of Neuroscience Research · doi:10.1002/jnr.25017 · Cited by 21
Ayahuasca, a potentially rapid acting antidepressant: focus on safety and tolerability
Rossi, G. N., Dias, I. C. D. S., Baker, G. B., Bouso, J. C., Dursun, S. M., Hallak, J. E. C., & SANTOS, R. G. D. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2054988 · Cited by 23
Menéndez-Quintanal, L. M., Matey, J. M., González, V. D. F., Serrano, B. B., Hernández-Díaz, F. J., Zapata, F., Montalvo, G., & García‐Ruiz, C. (2024) · Psychoactives · doi:10.3390/psychoactives3040033 · Cited by 23
The current state of ayahuasca research in animal models: A systematic review
Daldegan‐Bueno, D., Simionato, N. M., Favaro, V. M., & Maia, L. O. (2023) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2023.110738 · Cited by 21
A Phase 1 single ascending dose study of pure oral harmine in healthy volunteers
Ables, J. L., Israel, L., Wood, O., Govindarajulu, U. S., Fremont, R. T., Banerjee, R., Liu, H., Cohen, J., Wang, P., Kumar, K., et al. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241273772 · Cited by 20
The dark web trades wildlife, but mostly for use as drugs
Stringham, O., Maher, J., Lassaline, C. R., Wood, L., Moncayo, S., Toomes, A., Heinrich, S., Watters, F., Drake, C., Chekunov, S., et al. (2023) · People and Nature · doi:10.1002/pan3.10469 · Cited by 19
Heal, D. J., Gosden, J., Smith, S. L., & Atterwill, C. K. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109375 · Cited by 19
Effects of psychedelics on neurogenesis and broader neuroplasticity: a systematic review
da Cruz, R. V. L., Leão, R. N., & Moulin, T. C. (2024) · Molecular Medicine · doi:10.1186/s10020-024-01013-4 · Cited by 19
Egger, K., Gudmundsen, F., Jessen, N. S., Baun, C., Poetzsch, S. N., Shalgunov, V., Herth, M. M., Quednow, B. B., Martin-Söelch, C., Dornbierer, D., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1140656 · Cited by 19
Daldegan‐Bueno, D., Révész, D., Morais, P. R., Barbosa, P. C. R., & Maia, L. O. (2022) · Substance Use & Misuse · doi:10.1080/10826084.2022.2063896 · Cited by 20
Effects of hallucinogenic drugs on the human heart
Neumann, J., Dhein, S., Kirchhefer, U., Hofmann, B., & Gergs, U. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1334218 · Cited by 16
Evidence on the impairing effects of Ayahuasca on fear memory reconsolidation
Daneluz, D. M., Sohn, J. M. B., Silveira, G. D. O., Yonamine, M., & Stern, C. A. J. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06217-2 · Cited by 17
Egger, K., Redondo, J. J., Müller, J., Dornbierer, J., Smallridge, J. W., Aicher, H., Meling, D., Müller, P., Kost, J., Puchkov, M., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117908 · Cited by 14
Psychedelic-related deaths in England, Wales and Northern Ireland (1997–2022)
Kopra, E. I., Penttinen, J., Rucker, J., & Copeland, C. S. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111177 · Cited by 12
Nižňanský, Ľ., Nižnanská, Ž., Kuruc, R., Szórádová, A., Šikuta, J., & Zummerová, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11041147 · Cited by 13
Yeast Platforms for Production and Screening of Bioactive Derivatives of Rauwolscine
Bradley, S. A., Hansson, F. G., Lehka, B. J., Rago, D., Pinho, P. G. L. F., Peng, H., Adhikari, K. B., Haidar, A. K., Hansen, L. G., Volkova, D. A., et al. (2024) · ACS Synthetic Biology · doi:10.1021/acssynbio.4c00039 · Cited by 11
Chaves, C., SANTOS, R. G. D., Dursun, S. M., Tusconi, M., Carta, M. G., Brietzke, E. M., & Hallak, J. E. C. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1485337 · Cited by 11
Clinical Pharmacokinetics of N,N-Dimethyltryptamine (DMT): A Systematic Review and Post-hoc Analysis
van der Heijden, K. V., Otto, M. E., Schoones, J. W., van Esdonk, M. J., Borghans, L. G. J. M., van Hasselt, J. G. C., van Gerven, J., & Jacobs, G. (2025) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01450-8 · Cited by 13
Mueller, M. J., Aicher, H., Dornbierer, D., Marten, L., Suay, D., Meling, D., Elsner, C., Wicki, I. A., Müller, J., Poetzsch, S. N., et al. (2024) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaf001 · Cited by 10
Du, H., Song, J., Ma, F., Gao, H., Zhao, X., Mao, R., He, X., & Yan, Y. (2023) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2023.2281893 · Cited by 10
Amr, A. E. E., Kamel, A. H., Almehizia, A. A., Sayed, A. Y. A., & Abd‐Rabboh, H. S. M. (2021) · Molecules · doi:10.3390/molecules26020324 · Cited by 10
Kadyan, P., & Singh, L. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00602-8 · Cited by 10
Potential therapeutic use of ayahuasca: A literature review
Costa, S. P. M., CARVALHO, K. C., GOMES, I. N., Calazans, C. L., Silva, M. T. A., de Miranda, J. A., Barreto, I. C., Matheus Vinícius Guimarães de, M. E. L. O., de Holanda, K. E. R., & Filho, J. M. T. D. A. (2024) · Acta Amazonica · doi:10.1590/1809-4392202301821 · Cited by 8
Predescu, I.-A., Jîjie, A.-R., Pătrașcu, D., Pasc, A.-L.-V., Piroș, E. L., Trandafirescu, C. M., Oancea, C. I., Dehelean, C. A., & Moacă, E.-A. (2025) · Pharmacy · doi:10.3390/pharmacy13010007 · Cited by 7
Joga, R., Yerram, S., Patnam, J. D., Choudhary, K. K., Varpe, P. C., Raghuvanshi, R. S., & Srivastava, S. (2025) · Health Policy · doi:10.1016/j.healthpol.2025.105392 · Cited by 7
Preliminary evidence of links between ayahuasca use and the corpus callosum
Simonsson, O., Bouso, J. C., Kurth, F., de Araújo, D. B., Gaser, C., Riba, J., & Eileen Luders, A. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1002455 · Cited by 6
Toxicological Analysis of Drugs in Human Mummified Bodies and Proposed Guidelines
Silva-Bessa, A., Dinis‐Oliveira, R. J., Forbes, S. L., & Ferreira, M. T. (2022) · Current Drug Research Reviews · doi:10.2174/2589977514666220914084543 · Cited by 6
Self-citationAl-Imam, A., Motyka, M. A., Hoffmann, B., Magowska, A. M., & Michalak, M. (2023) · Pharmaceuticals · doi:10.3390/ph16060831 · Cited by 6
Xiao, Y., Yuan, S., Luo, R., Zhu, R., Zheng, Q., Di, B., & Xiang, P. (2025) · Journal of Chromatography B · doi:10.1016/j.jchromb.2025.124659 · Cited by 5
Introduction to the chemistry and pharmacology of psychedelic drugs
Walker, S. R., Pullella, G. A., Piggott, M., & Duggan, P. J. (2023) · Australian Journal of Chemistry · doi:10.1071/ch23050 · Cited by 5
Contreras‐Puentes, N., Amador, A. A., & Manzur-Villalobos, I. (2022) · Journal of Herbmed Pharmacology · doi:10.34172/jhp.2022.25 · Cited by 5
Síndrome serotoninérgico inducido por ayahuasca: a propósito de un caso
Ortega-Muñoz, L., Laura Herrera, D., Uribe, P. C., & Julián Benítez, M. (2024) · Revista chilena de neuro-psiquiatría · doi:10.4067/s0717-92272024000200184 · Cited by 4
Drug-induced psychosis following use of Ayahuasca: a presentation to forensic psychiatric services
Baker, M., & O'Shea, C. I. (2024) · BMJ Case Reports · doi:10.1136/bcr-2024-260648 · Cited by 4
Quantitative analysis of recreational psychoactive mushroom gummies in Portland, Oregon
Correia, M. S., Gonzaga, M., Temple, C., & Gerona, R. R. L. (2025) · Clinical Toxicology · doi:10.1080/15563650.2025.2450240 · Cited by 4
Neumann, J., Dietrich, T., Azatsian, K., Hofmann, B., & Gergs, U. (2025) · Scientific Reports · doi:10.1038/s41598-025-91400-6 · Cited by 4
Sun, C., Yi, J., Wei, F., Lv, X., Deng, S., Zhang, B., Zhao, W., & Ma, X. (2021) · Fitoterapia · doi:10.1016/j.fitote.2021.105054 · Cited by 4
Pharmacological Properties of Psychedelics with a Special Focus on Potential Harms
Holze, F., Liechti, M. E., & Müller, F. (2024) · Current topics in behavioral neurosciences · doi:10.1007/7854_2024_510 · Cited by 5
Psilocybin and magic mushrooms: Patterns of abuse and consequences of recreational misuse
Brito-da-Costa, A. M., da Silva, D. D., Madureira-Carvalho, Á., & Dinis‐Oliveira, R. J. (2022) · Springer eBooks · doi:10.1007/978-3-030-67928-6_130-1 · Cited by 4
Self-citationOuédraogo, W. R. C., Belemnaba, L., Nitiéma, M., Kaboré, B., Compaoré, S., Koala, M., Semdé, R., & Ouédraogo, S. (2023) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v13i1.5819 · Cited by 4
Substance Use and the Nervous System
Stitt, D. W. (2023) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001234 · Cited by 4
Analgesic and Antidepressant Activity of 8-Substituted Harmine Derivatives
Сейдахметова, Р. Б., Аманжан, А., Shults, E. E., Goldaeva, K. V., Adekenov, S. M., & Berillo, D. A. (2022) · Chemistry of Heterocyclic Compounds · doi:10.1007/s10593-022-03092-9 · Cited by 4
Thomas, K. L. H., Jesse, R., Mehtani, N. J., Mitchell, J., & Anderson, B. T. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2201244 · Cited by 4
Schuman, H. D. M., Barkova, S., Mina, R., Deleemans, J. M., Nguyen, T. T.-T. N., & Carlson, L. E. (2025) · Integrative Cancer Therapies · doi:10.1177/15347354251370982 · Cited by 3
Puigseslloses, P., Nadal‐Gratacós, N., Fumàs, B., Modenutti, C. P., Pottie, E., Ortigosa, J., Pablo-Quesada, A., Riera-Colomer, C., Ettcheto, M., Berzosa, X., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03308-2 · Cited by 4
Carmona, E. R., & Selfene, A. C. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.121040 · Cited by 3
Lima, G., Soares, C., Teixeira, M., & Castelo-Branco, M. S. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16264 · Cited by 3
Äbelö, A., Smallridge, J. W., von Rotz, R., Dornbierer, D., Egger, K., Ashton, M., & Scheidegger, M. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118329 · Cited by 3
Toxicology and Pharmacological Interactions of Classic Psychedelics
Thomas, K. L. H. (2024) · Current topics in behavioral neurosciences · doi:10.1007/7854_2024_508 · Cited by 4
Garcia, M. R., Ferreres, F., Mineiro, T., Videira, R. A., Gil‐Izquierdo, Á., Andrade, P. B., Seabra, V., da Silva, D. D., & Gomes, N. G. M. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118915 · Cited by 3
Self-citationDinis‐Oliveira, R. J. (2022) · Psychoactives · doi:10.3390/psychoactives1010001 · Cited by 3
Self-citationDesign and synthesis of beta-Arrestin-biased 5HT2AR agonists
D’Andrea, L. (2023) · VBN Forskningsportal (Aalborg Universitet) · doi:10.54337/aau528157052 · Cited by 3
Kuypers, K. P. C., Mason, N. L., Carlier, A., Totomanova, I., & Haijen, E. C. H. M. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03801-2 · Cited by 2
Behavioral characterization of ayahuasca treatment on Wistar rats in the open field test
Farias, C. P., Victoria, P. P., Xavier, J., Sekine, F. G., Ribeiro, E. S., Cognato, G. D. P., & de Carvalho, H. W. (2022) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s2175-97902022e21110 · Cited by 2
Tran, J., Elkins, A. C., Vassiliadis, S., Cogan, N. O. I., & Rochfort, S. J. (2024) · Psychoactives · doi:10.3390/psychoactives3040032 · Cited by 2
Videira, N. B., Nair, V., Paquet, V., & Calhoun, D. (2023) · Journal of Applied Toxicology · doi:10.1002/jat.4533 · Cited by 2
Satu Saudara: Pelaksanaan Pendidikan Multikultural di TK X Kabupaten Jember
Husnah, I., Wardhani, W. D. L., & Adwitiya, A. B. (2023) · Jurnal Pendidikan Anak Usia Dini · doi:10.47134/paud.v1i1.33 · Cited by 3
Lin, J., Yun, K., Sun, Q., Xiang, P., Wu, L., Yang, S., Dun, J., Fu, S., & Chen, H. (2023) · Forensic Sciences Research · doi:10.1093/fsr/owad014 · Cited by 2
Akdoğan, M., Tekman, E., Yuca, H., Karakaya, S., Bona, G. E., & Kazaz, C. (2025) · Ankara Universitesi Eczacilik Fakultesi Dergisi · doi:10.33483/jfpau.1532753 · Cited by 1
Husaini, D. C., Chiroma, J. H., Nwachukwu, I. E., Sani, G. M., & Orisakwe, O. E. (2025) · Beni-Suef University Journal of Basic and Applied Sciences · doi:10.1186/s43088-025-00653-7 · Cited by 1
Wittayakarn, N., Tan, Y., Choomalaiwong, P., Chen, S., Hoer, D. R., Thaoboonruang, N., & Lohitnavy, M. (2025) · Toxicological Sciences · doi:10.1093/toxsci/kfaf118 · Cited by 1
Kermanshah, A., Stapleton, M., Mauriello, C. M., Cobas, M., & Torres, I. T. C. (2025) · Cureus · doi:10.7759/cureus.92568 · Cited by 1
Brache, K., & Diazgranados, M. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1729887 · Cited by 1
Fatalities following DMT use: two case reports and a review of the literature
Pullen, J., Moore, R., Wood, R., Rab, E., Couchman, L., & Copeland, C. S. (2025) · Journal of Analytical Toxicology · doi:10.1093/jat/bkaf064 · Cited by 1
The DEA report on ayahuasca risks: “Science” in service of prohibition?
Labate, B. C., Ermakova, A. O., Sloshower, J., Coelho, N. L. G., Palhano-Fontes, F., Antunes, H. F., de Assis, G. L., Cavnar, C., de Araújo, D. B., & Ribeiro, S. T. G. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2023.00279 · Cited by 1
dos Santos, B. C., Reis, A. K. G., Nucci, R. A. B., Campos, A. C. P., Martins, D. O., Daldegan‐Bueno, D., & Pagano, R. L. (2024) · Brain Behavior and Immunity Integrative · doi:10.1016/j.bbii.2024.100087 · Cited by 1
Greene, S. L. (2025) · Comprehensive analytical chemistry · doi:10.1016/bs.coac.2024.12.002 · Cited by 1
Psilocybin and Magic Mushrooms: Patterns of Abuse and Consequences of Recreational Misuse
Brito-da-Costa, A. M., da Silva, D. D., Madureira-Carvalho, Á., & Dinis‐Oliveira, R. J. (2022) · Springer eBooks · doi:10.1007/978-3-030-92392-1_130 · Cited by 1
Self-citationThe Ontological Status of Visions and Hallucinations.Preprint
Blaber, R. M. (2022) · doi:10.31235/osf.io/vmakg · Cited by 1
Ayahuasca in the treatment of bipolar disorder with psychotic features–A retrospective case studyPreprint
Turkia, M. (2023) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/65se9 · Cited by 2
(2022) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s2175-97902022e19373e
Madureira-Carvalho, Á., Brito-da-Costa, A. M., Dias-da-Silva, D., & Dinis‐Oliveira, R. J. (2022) · Toxicology Letters · doi:10.1016/j.toxlet.2022.07.282
Self-citationIsHak, W. W., Magakian, N., Ishak, W. W., Mikhail, A. A., & Lim, R. F. (2023) · Springer eBooks · doi:10.1007/978-3-031-15401-0_25
Klassieke psychedelica: veiligheid, neveneffecten en medicatie-interacties
Geleyn, E., Kuypers, K. P. C., Seynaeve, M., & Lemmens, G. M. D. (2023) · Tijdschrift voor Geneeskunde · doi:10.47671/tvg.79.23.049
Corrigendum to: Introduction to the chemistry and pharmacology of psychedelic drugs
Walker, S. R., Pullella, G. A., Piggott, M., & Duggan, P. J. (2024) · Australian Journal of Chemistry · doi:10.1071/ch23050_co
Santos, F. P. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.9.2023.tde-12122023-105953
Kerna, N. A., Pruitt, K. D., Carsrud, N. D. V., Kadivi, K., Ngwu, D. C., Holets, H. M., Flores, J. V., Nnake, I., Azi, C. I., Anderson, J., et al. (2024) · European Journal of Arts Humanities and Social Sciences · doi:10.59324/ejahss.2024.1(3).10
Metadata
- Authors
- Brito-da-Costa, A. M., Dias-da-Silva, D., Gomes, N. G. M., Dinis-Oliveira, R. J., & Madureira-Carvalho, Á.
- Affiliations
- Cooperativa de Ensino Superior Politécnico e Universitário (PT)
- Department of Sciences, IINFACTS-Institute of Research and Advanced Training in Health Sciences and Technologies, University Institute of Health Sciences (IUCS), CESPU, CRL, 4585-116 Gandra, Portugal
- Universidade do Porto (PT)
- ORCID
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2020-10-23
- Volume
- 13
- Issue
- 11
- Pages
- 334
- ISSN
- 1424-8247 (ISSN-L)
- PMC
- PMC7690791
- OpenAlex
- W3094461574
- Cited by
- 117
- References
- 218
- Citations by year
- 2026: 13 · 2025: 24 · 2024: 25 · 2023: 22 · 2022: 25 · 2021: 7
- FWCI
- 1.06
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceuticals (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Alkaloids: synthesis and pharmacology
- Keywords
- ayahuasca, N,N-dimethyltryptamine, harmine, harmaline, tetrahydroharmine, harmala alkaloids, toxicokinetics, toxicodynamics, monoamine oxidase A inhibition, Psychotria viridis, Banisteriopsis caapi, 5-HT2A receptor, forensic toxicology, psychedelic therapy, depression, anxiety, substance use disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review